These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37985171)

  • 21. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
    Seipelt G; Böhme A; Koschmieder S; Hoelzer D
    Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.
    Van Damme M; Crompot E; Meuleman N; Maerevoet M; Mineur P; Bron D; Lagneaux L; Stamatopoulos B
    Clin Epigenetics; 2016; 8():132. PubMed ID: 27980696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemophagocytic lymphohistiocytosis as a consequence of untreated B-cell chronic lymphocytic leukaemia.
    Bailey C; Dearden C; Ardeshna K
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28446487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leukaemia cutis after starting bendamustine: cause or coincidence?
    Mawri S; Nabi S; Jallad B; Won J
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26392439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
    Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
    Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemophagocytosis in a patient with persistent chronic lymphocytic leukemia.
    Kamangar E; Zhao W
    Blood; 2013 Sep; 122(13):2149. PubMed ID: 24195125
    [No Abstract]   [Full Text] [Related]  

  • 27. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
    Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
    Sharman JP; Burke JM; Yimer HA; Boxer MA; Babu S; Li J; Mun Y; Danilov AV;
    Leuk Lymphoma; 2021 Apr; 62(4):791-800. PubMed ID: 33243049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
    Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
    Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
    Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Cassin R; D Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Olivieri J; Cutrona G; Rossi D; Cuneo A; Di Raimondo F; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
    Am J Hematol; 2021 Aug; 96(8):E269-E272. PubMed ID: 33878220
    [No Abstract]   [Full Text] [Related]  

  • 32. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    Cramer P; Langerbeins P; Eichhorst B; Hallek M
    Eur J Haematol; 2016 Jan; 96(1):9-18. PubMed ID: 26332019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study].
    Stadnik EA; Strugov VV; Andreeva TO; Virts YV; Rumyantsev AM; Mirolyubova YV; Butylin PA; Zaritsky AY
    Ter Arkh; 2017; 89(7):57-64. PubMed ID: 28766542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GM-CSF treatment in patients with B-chronic lymphocytic leukemia.
    de Nully Brown P; Hansen MM
    Leuk Lymphoma; 1999 Jan; 32(3-4):365-8. PubMed ID: 10037035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis.
    Goel S; Polski JM; Imran H
    Ann Clin Lab Sci; 2012; 42(1):21-5. PubMed ID: 22371906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
    Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.